The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma. The Food and Drug ...

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) The following represents disclosure information provided by authors ...

Kaposi sarcoma, a type of vascular cancer once only seen in elderly people of Jewish or Mediterranean descent, is one of the two most common opportunistic diseases associated with AIDS. Its spread, ...

Patients with HIV-negative Kaposi sarcoma (KS) can be successfully treated with immunotherapy even if they also have psoriasis or other skin conditions, according to a new case report. The paper ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® ...

Introduction KAPOSI'S sarcoma, or "idiopathic multiple hemorrhagic sarcoma," was first described as a clinical entity by Kaposi in 1872. The disease is progressive, and it exhibits a wide range of ...

Author(s)Amy Paturel, M.S., M.P.H. A rare virus coupled with an ailing immune system can lead to Kaposi’s sarcoma. Restoring immune function can help fight it. Alex C.* was a teenager in 2007 when ...

While speaking at the handover ceremony of the National Aids Council (NAC) support to KIDZCAN for child cancer initiatives, ...

The "Kaposi Sarcoma - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Kaposi Sarcoma was estimated at US$162.3 Million in 2023 and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to pomalidomide (Pomalyst, Bristol-Myers Squibb) for the treatment of AIDS-related Kaposi sarcoma that is resistant to highly ...

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) The following represents disclosure information provided by authors ...